vs. 37%; p=0.43). Conclusions: The incidence of ADHF after sepsis and septic shock is low and is non-significantly higher in patients with SRMD.
Learning Objectives: The Third International Consensus Definitions for Sepsis and Septic Shock now define sepsis as an abnormal host response to infection culminating in organ dysfunction. This new definition is accompanied by diagnostic tools that rely on organ dysfunction rather than inflammation (i.e., SIRS criteria) and include the quick sequential (sepsis-related) organ failure assessment score (qSOFA). It is unclear whether the transition to organ failure assessment will influence the reported rates of sepsis and its clinical outcomes. The purpose of this study was to measure the agreement between qSOFA and SIRS criteria in patients located outside the ICU with suspected infection and examine the relationship between these diagnostic tools and clinical outcomes. Methods: A single clinician performed a diagnostic assessment for sepsis using qSOFA and SIRS criteria on consecutive adult patients (>18 yrs) presenting to our Critical Care Outreach Service for any indication (e.g., change in vital signs). We used published standards to determine whether a patient met criteria for sepsis, and retrospectively reviewed the medical record to obtain clinical outcomes. Results: One hundred forty-eight patients were evaluated by the service (age: 67 ± 18 years; 46% F). Using qSOFA and SIRS criteria, 41% (61) and 42% (63) of patients (r = 0.69) met criteria for sepsis, respectively. The overall disagreement between qSOFA and SIRS criteria was 14.8% (22/148). For the entire cohort, all-cause 28-day mortality was 21% and hospital length of stay was 12 days. After adjusting for age, gender and DNR status, the OR for mortality using qSOFA and SIRS criteria was 6.4 (p=0.001) and 12.1(p<0.001), respectively. Conclusions:In patients with known or suspected sepsis, the simple clinical criteria used in qSOFA identified a similar prevalence of sepsis as compared to SIRS criteria, and were associated with significant mortality. A positive qSOFA score may be a useful tool to alert the clinician to escalate care in patients with known or suspected sepsis. Larger prospective observational studies are needed to validate this observation.
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SEPSIS-3 APPLIED TO A HISTORICAL COHORT OF SEVERE SEPSIS PATIENTS TREATED OUTSIDE THE ICU
David Tannehill, Brett Sharpe, Melinda Miller, Ammar Saifo, Jackyln O'Brien, Christopher Veremakis, Jan Kasal Learning Objectives: SEPSIS-3 included a proposed clinical score, qSOFA, intended to screen non-ICU patients (pts) with suspected infection at risk of poor outcomes. Since 2013, our institution has used a sepsis program that combines automated EHR screening with centralized monitoring to provide earlier identification and improve adherence to Surviving Sepsis Campaign (SSC) guidelines. The purpose of this study is to describe how a transition to SEP-SIS-3 definitions and applying qSOFA to our existing process would change the patient population identified by the program. Methods: Severe sepsis (SS) pts admitted to a non-ICU environment in an 859-bed tertiary care hospital between 11/2013 and 5/2016 were evaluated retrospectively using a sepsis database. Demographic data included age, gender, weight and SOFA scores. Diagnosis of SS was based on the previous SSC definition. Pts were identified by our computerized algorithm. Elements of qSOFA (RR >22, SBP<100mmHg and mental status) were retrospectively evaluated and scores generated. Pts were separated into two groups: Pts with SOFA score of 0 or 1 who would not fit the SEPSIS-3 definition of sepsis, and pts with SOFA score of ≥2 who would fit the SEPSIS-3 definition. Results: 549 SS pts were identified. Mortality was 2.9%. 1.5% mortality among pts with a SOFA score of ≤1 and 3.7% mortality among pts with a SOFA score of >2. There were 196 pts (36%) with a SOFA score of ≤1 who would not meet the SEPSIS-3 definition. 44 of the 196 pts (22%) would have screened positive for qSOFA criteria. 353 pts (64%) had a SOFA score of ≥2, fulfilling the SEPSIS-3 definition. Within this group, 180 of 353 pts (51%) would have screened positive for qSOFA criteria. Application of qSOFA in screening for sepsis in non-ICU pts identified by our program would have a 51% sensitivity (CI 45.7% to 56.3%) and 78% specificity (CI 71.1% to 83.2%) resulting in a +LR of 2.27 (CI 1.72 to 3). Conclusions: Applying SEPSIS-3 to our sepsis program could mean 36% fewer non-ICU patients entered into our program and the sensitivity and specificity of qSOFA as a screening tool for sepsis may be limited.
CLINICAL IMPLICATIONS OF THE PLASMA EPHA2 RECEPTOR LEVEL IN PATIENTS WITH SEPSIS
Kyung Soo Chung, Chi Young Kim, Su Hwan Lee, Se Kyu Kim, Joon Chang, Youngsam Kim Learning Objectives: The Eph/ephrin receptor ligand system is known to play a role in inflammation. The present study aimed to evaluate associations of the plasma EphA2 receptor level in critically ill patients with sepsis. Methods: This was an retrospective cohort study of prospectively collected samples and clinical data at the medical intensive care unit (MICU) of a 2000-bed university tertiary referral hospital in South Korea. Plasma was collected within 24 h of MICU admission and the biomarkers were measured using a Human Magnetic Luminex® Screening Assay kit (R&D Systems, Inc., Minneapolis, MN, USA) Results: This study analyzed 145 patients with systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, or septic shock who were admitted to the MICU. Positive correlations of the plasma EphA2 receptor level with the acute physiology and chronic health evaluation (APACHE II) score (r = 0.291, P < 0.001) and sepsis-related organ failure (SOFA) score were observed (r = 0.341, P< 0.001). The area under the curve (AUC) for the plasma EphA2 receptor level on a receiver operating characteristic curve was 0.690 (95% confidence interval [CI], 0.608-0.764); the AUCs for the APACHE II score and SOFA score were 0.659 (95% CI, 0.576-0.736) and 0.745 (95% CI, 0.666-0.814), respectively. A Cox proportional hazard model identified an association between an increased plasma EphA2 receptor level (≥ 51.5 pg mL-1) and increased risk of 28-day mortality in the MICU (hazard ratio = 3.22, 95% CI, 1.709-6.049). Conclusions: An increased plasma EphA2 receptor level was associated with sepsis severity and 28-day mortality among sepsis patients. The plasma EphA2 receptor could be considered a new potential treatment target in sepsis patients and used as a target monitor for EphA2 receptor blocker therapy.
